stockportfolio.pro
Stocks / DNTH vs TVTX
DNTH vs TVTX
Dianthus Therapeutics, Inc. and Travere Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Dianthus Therapeutics, Inc. (DNTH) | Travere Therapeutics, Inc. (TVTX) | |
|---|---|---|
| Market cap | $4.4B | $4.5B |
| Revenue (latest FY) | $2.04M | $490.73M |
| Net income (latest FY) | $-162.34M | $-25.55M |
| Revenue growth (5y CAGR) | — | 19.9% |
| Net margin | -7973.3% | -5.2% |
| Return on equity | -32.9% | -22.2% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DNTH — free Open TVTX — freeFrequently asked questions
Which is bigger, DNTH or TVTX?
Travere Therapeutics, Inc. is larger by market capitalization — $4.5B versus $4.4B.
Which grows faster, DNTH or TVTX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.